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Background: Despite several publications strongly advocating prophylactic antibiotics during leech therapy, and recent primary articles
shedding new light on the microbiota of leeches, many units either do not use antibiotic prophylaxis, or are continuing to use ineffective
agents. Methods: A 5-year follow-up of plastic surgery units in the United Kingdom and the Republic of Ireland was conducted in 2007 to
ascertain current practice regarding the use of prophylactic antibiotics with leech therapy. A comprehensive literature search investigated
primary research articles regarding the microbiota of leeches to update the reconstructive surgery community. Results: Despite published
evidence to support the use of prophylactic antibiotics during leech therapy, 24% of units do not use antibiotic prophylaxis and 57% of
those using antibiotics are using potentially ineffective agents. Advanced molecular genetic techniques, which allow accurate characteriza-
tion of both culturable and nonculturable microbiota of the leech digestive tract, show a wider diversity than at ﬁrst thought, with variable
antiobiotic resistance proﬁles. Conclusions: Despite infection due to leech therapy being a well known and relatively common complication,
many units are not using appropriate antibiotic prophylaxis. VC 2009 Wiley-Liss, Inc. Microsurgery 29:619–625, 2009.
Blood letting and the therapeutic use of medicinal
leeches dates back to ancient Egypt.1 Decades of reports
of leech therapy in plastic and reconstructive surgery2
and more recently the application of leeching for diverse
medical problems such as chronic pain syndromes associ-
ated with degenerative diseases3–5 have given leech ther-
apy multiple roles in modern day medicine. Their popu-
larity has indeed varied over the years, having been used
by plastic,6–9 maxillofacial,10 and other reconstructive
surgeons11,12 to aid salvage of compromised pedicled
ﬂaps,2,13 microvascular free-tissue transfers,6,14–16
venously congested digits,8,17–24 nipples,25,26 ears,27–32
lips,33,34 nasal tips,11,35 and even the penis.12 Peer-
reviewed evidence suggests that the survival of compro-
mised, venous-congested tissues is improved by early
application of a leech.36–38 The leech simulates venous
circulation until the congested tissue reestablishes venous
capillary circulation. The beneﬁts of leech therapy were
only relatively recently acknowledged with The Food and
Drug Administration of the United States approving the
use of Hirudo medicinalis as a medical device in 2004.39
While most commercial suppliers sell medicinal leeches
as H. medicinalis, a recent study revealed that the annel-
ids sold were genetically distinct from H. medicinalis and
were identiﬁed as H. verbana by Siddall et al.40 Bely
et al. encourage the increased use of ‘‘DNA Barcodes’’
such as COI gene sequences to reveal genetic variations
in leeches,41 while DeSalle et al. advocate a more cau-
tious approach until the barcode reader is reliable and the
taxonomic community is in agreement.42 Whether clariﬁ-
cation of these differences will have any medical or
microbiological importance remains to be demonstrated.
In this study, we refer to medicinal leeches as H. medici-
nalis unless the animals were speciﬁcally identiﬁed as H.
verbana. An overview of the anatomy, physiology, and
mechanisms of action of the medicinal leech relevant to
the reconstructive surgeon is summarized elsewhere.43
A high incidence of infection during and after appli-
cation of medicinal leeches has been widely reported de-
spite external decontamination. The exact incidence of
leech-associated infection associated with postoperative
use is difﬁcult to assess, with incidences ranging from
2.4% to 36.2% being reported in the literature8,36,44–46
(see Table 1). At least one clinical study has demon-
strated that limiting leech application to tissue with clear
evidence of arterial circulation while giving patients anti-
biotics effective against leech enteric ﬂora during leech
therapy can eliminate leech-related soft-tissue infection.47
Despite several publications advocating prophylactic anti-
biotics to combat leech-borne infections,7–9,44,48–52 we
were aware of many units either not using antibiotic pro-
phylaxis at all, or continuing to use inappropriate agents.
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With the knowledge of the microbiota of the leech di-
gestive tract continuing to grow, the last decade has
shown that the bacterial community is much more com-
plex than previously documented. More accurate identiﬁ-
cation and antibiotic sensitivity testing has allowed an ex-
ponential increase in relevant data regarding leech micro-
biota. A limitation of the clinical articles that previously
characterized the digestive tract microbiota of leeches
was that these studies were purely culture based. It is
now widely recognized that >99% of microbes are at
present unculturable53 and modern techniques must be
used to identify theses symbionts.
In this article we present the results of a 5-year fol-
low-up national survey of antiobiotic prophylaxis during
leech therapy and draw on the combined wisdom of both
the microbiological and plastic surgery community to dis-
cuss the implications of our ﬁndings including an up-to-
date discussion concerning leech borne infections and
appropriate evidence-based treatment.
METHODS
A telephone survey of all 62 plastic surgery units in
the United Kingdom and the Republic of Ireland was
conducted in August 2007. The names, addresses, and
phone numbers were obtained from the British Associa-
tion of Plastic, Reconstructive and Esthetic Surgeons
Website (www.bapras.co.uk). Information was obtained
from the senior sister on the Plastic and Microsurgery
ward who had ﬁrst hand experience of the use of leeches
on the unit, and was responsible for the supervision of
antibiotic administration and leech application.
Five simple questions were asked:
1. Are leeches used postoperatively by the plastic sur-
geons in your unit?
2. How many times per year on average are leeches
used?
3. Do you use antibiotics routinely postoperatively when
leeches are applied?
4. If yes: What antibiotics do you use?
5. Were there written protocols for the use of leeches?
This questionnaire was accompanied by an extensive
literature search to investigate primary research papers
regarding the microbiota of leeches and update the
reconstructive surgery community.
RESULTS
Accurate information was gained from 55 of the 62
units (89% response rate). Of these, 49 (90%) had used
leeches postoperatively in the salvage of compromised
free ﬂaps or digital replants within the last 5 years. On
average, 23 units used leeches one to ﬁve times per year,
15 units used leeches 6–10 times per year, four units
used leeches 11–15 times per year, and seven units used
leeches more than 16 times per year. Twelve units
(24.5%) did not use any antibiotic prophylaxis before or
during leech therapy. The remaining 37 units used a
range of prophylactic antibiotics routinely during leech
application including coamoxiclav, metronidazole, benzyl
penicillin, ciproﬂoxacin, and ﬂucloxacillin. Written proto-
cols concerning the use of leeches were available in 39
units (80%) and 49 units (100%) routinely kept leeches
in the hospital pharmacy overnight (see Figs. 1–4). In the
ﬁgures, ‘‘other’’ antibiotics include metronidazole, cepha-
losporins, and trimpethoprim.
DISCUSSION
This study conﬁrms that the majority of plastic sur-
gery units in the United Kingdom and Ireland use medic-
inal leeches to improve drainage from venously con-
gested tissues or extremity replants postoperatively, but
despite strong supportive evidence, 24.5% of units fail to
use any antibiotic prophylaxis. The total percentage of
units using prophylactic antibiotics has decreased from
2002 to 2007 from 92.5% to 75.5%, although the number
of units using reliably effective antibiotics such as ﬂuo-
roquinolones has improved from 22% in 2002% to 43%
in 20079 (see Fig. 4).
Leech-Borne Infection: Clinical Aspects
The leech bite is created by three jaws, each contain-
ing 60–100 pairs of cutting teeth, forming the characteris-
tic Y-shaped tri-radiate conformation 1 mm in diameter
and up to 1.5 mm in depth.54,55 These specially adapted
jaws pierce the host tissues in order to feed on blood.
The combination of local tissue damage, along with con-
tact between the oral and digestive tract ﬂora (including
both the leech crop and intestine) and the patient means
that a potential for infection exists. Although the use of
leeches in the treatment of arthritis and other medical
conditions seems to be associated with negligible risks of
infection, the venous congestion in plastic surgery
patients requiring treatment seems to lead to a localized
Table 1. Chronological Table Summarizing the Published Infection






rate (%) Authors Year
30 3 20 Mercer et al.45 1987
42 Not stated 7 Lineaweaver et al.8 1992
18 5 11 De Chalain et al.36 1996
122 5 4.1 Sartor et al.46 2002
47 2 36.2 Bauters et al.44 2007
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area of immunocompromise that is more susceptible
to infection. The exact incidence of infection is difﬁcult
to assess, with incidences ranging from 2.4% to
36.2%8,36,44–46 being reported in the literature.
Extensive studies have been carried out on the sur-
face, mouth, and digestive tract microbiota of leeches,
which show Aeromonas spp. to be prominent in the resi-
dent ﬂora.36,47,48,53,56–60 The most recent of these primary
research articles was able to identify both culturable and
unculturable isolates. The most common clinical presenta-
tion of Aeromonas infection in humans is of celluli-
tis,61,62 often with a foul odor, complicated by subcutane-
ous abscess formation. In severe cases, extensive tissue
loss and septicemia has been reported.63 Aeromonas
seems to have an afﬁnity for muscle tissue, and is
capable of producing extensive proteolytic enzymes lead-
ing to a picture resembling clostridial myonecrosis with
gas production.64 Of most concern to microsurgeons is
the ability of Aeromonas to invade the walls of blood
vessels with resultant vasculitis, thrombosis, and hemor-
rhagic necrosis.65 In immunocompetent patients, surgical
site infections (SSIs) due to leech application may result
in additional antibiotic therapy, extended hospital stays,
rehospitalization, or removal of nonviable tissues.46 Cha-
lain’s meta-analysis reported on a total of 19 cases of
aeromonas infection (nine replants, three free ﬂaps, and
seven pedicled ﬂaps) with an overall salvage rate of the
tissues in the presence of infection of 31.8%, compared
with an expected salvage rate of 60–80% in noninfected
tissues.36 As one would expect, neutropenic and immuno-
compromised patients seem to be more at risk. Leech-
borne infections are by no means heterogenous in presen-
tation; delayed presentations have been recently reported
Figure 2. A bar chart showing the approximate number of cases
per year requiring leech therapy in each unit in the United Kingdom.
[Color ﬁgure can be viewed in the online issue, which is available
at www.interscience.wiley.com.]
Figure 3. A bar chart showing the percentage of United Kingdom units not using any antibiotic prophylaxis during leech therapy in 2007
compared with 2002. [Color ﬁgure can be viewed in the online issue, which is available at www.interscience.wiley.com.]
Figure 1. A pie chart showing the percentage of units in the United
Kingdom with and without a written protocol for leech therapy.
[Color ﬁgure can be viewed in the online issue, which is available
at www.interscience.wiley.com.]
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in escharotic ﬂaps66 and a case of meningitis due to
leech-borne infection has previously been reported.67
Leech-Borne Infection: Microbiology
Since 1976 three Aeromonas genospecies (Aeromonas
hydrophila, Aeromonas veronii, and Aeromonas caviae)
have been subdivided into 14 species.68 A combination of
molecular and biochemical studies has revealed the diges-
tive tract of H. verbana contained A. veronii69,70 and not
A. hydrophila. Soft-tissue infections due to A. hydrophila
have been widely reported as a complication of leech
application but may well be due to A. veronii,58 which
has a similar clinical presentation. Apart from A. hydro-
philia, pathogens causing wound infection following Hir-
udo therapy reported in the literature include Serratia
marcescens,71 Aeromonas sobria,72 and Vibrio ﬂuvialis.73
The accurate identiﬁcation is challenging because com-
mercial identiﬁcation kits frequently misidentify the spe-
cies and such kits could report A. veronii biovar sobria as
Aeromonas sobria. The single report of Vibrio ﬂuvialis
associated infection may well have been misnamed, as
the API20E method was used for identiﬁcation purposes
and the microbe was almost certainly an Aeromonad.74
The API20E1 test (bioMerieux) was used in the older
studies to identify Aeromonas species. Although it is still
used today, it is rather imprecise when compared with
molecular genetic analysis. The test consists of a plastic
strip of 20 individual, miniaturized tests tubes (cupules)
each containing a different reagent used to determine the
metabolic capabilities, and, ultimately, the genus and spe-
cies of enteric bacteria in the family Enterobacteraceae.
Interpretation of the 20 reactions plus a separate oxidase
reaction is converted to a digital code which is compared
with a known database of bacteria.
Knowledge of the diversity, virulence, and infections
caused by Aeromonas spp. continues to increase rap-
Figure 4. A bar chart showing the percentage of units using speciﬁc antibiotic prophylaxis in 2007 compared with 2002. [Color ﬁgure can
be viewed in the online issue, which is available at www.interscience.wiley.com.]
Figure 5. E test1 results showing the susceptibility of Aeromonas
veronii to ciproﬂoxacin (top center), the complete resistance to
ampicillin (middle left), and intermediate resistance to augmentin
(amoxycillin and clavulanic acid) (bottom middle). [Color ﬁgure can
be viewed in the online issue, which is available at www.interscience.
wiley.com.]
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idly.75 Of potential clinical importance is the increasing
incidence of multidrug resistance among Aeromonas spp.
isolates that have been observed in aquaculture world-
wide. This increasing incidence of resistance is due to
the horizontal transfer of mobile genetic elements such as
plasmids and class 1 integrons.76 High levels of resistance
to ﬁrst-generation cephalosporins44 and penicillins75–77 (via
b-lactamases), tetracyclines,76 and augmentin76–79 have
been observed in studies, whereas ﬂuoroquinoles seem to be
consistently active.44,48,57,66,75–77
We performed a preliminary study to illustrate the
antibiotic resistance proﬁle of A. veronii to plastic sur-
geons considering using leeches in their practice. We
identiﬁed a leech (H. medicinalis) by comparing with
color charts80 and isolated A. veronii in the laboratory
from the leech crop using previously described tech-
niques.81 The identity of Aeromonas was conﬁrmed
using the API20E test and more accurate molecular
genetic analysis. After plating a lawn of A. veronii, three
Etest1 strips comprising predeﬁned gradients of antibi-
otic concentrations on strips of plastic were used to
determine the on-scale minimum inhibitory concentration
(MIC in lg/ml) of ciproﬂoxacin, ampicillin, and aug-
mentin. Following 48 hours of incubation, the Etest1
results showed the susceptibility of A. veronii to cipro-
ﬂoxacin (top center), the complete resistance to ampicil-
lin (middle left), and intermediate resistance to augmen-
tin (bottom middle) (see Fig. 5).
One of the limitations of this study is the lack of cul-
ture-based data from patients with infections following
leech therapy. In an ideal world, a large prospective
study would report on the clinical outcome and infection
rate following leech therapy, along with an analysis of
the microbiota and resistance proﬁles. The use of leeches
is often a last resort, unplanned, and out of hours. Per-
sonal opinions and experience of their use varies from
surgeon to surgeon. To coordinate the collection and
analysis of this data would be incredibly difﬁcult consid-
ering the diversity of units using leeches and the lack of
a centralized database.
Considering the efﬁcacy of leeches, it would be
favorable to breed a germ-free leech. Unfortunately,
H. medicinalis’s obligatory symbiotic relationship with
A. veronii seems to preclude this.53,58,81–83 Future
research could potentially be targeted toward breeding
less pathogenic genotypes which retain only the proteo-
lytic determinants with the caveat that germ-free animals
are susceptible to colonization by potentially more viru-
lent bacteria.
CONCLUSIONS
Infection due to leech therapy is a well-known com-
plication with rates of up to 36.2% in recent studies.
Many units are not using appropriate antibiotic prophy-
laxis. There is known resistance of Aeromonas species to
commonly used agents such as penicillins and augmentin.
The recommended antibiotic at the present time is cipro-
ﬂoxacin, which has favorable resistance proﬁles and good
oral bioavailability.
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